



News and Views...

September 29, 2020

INDUSTRY NEWS



WHO Chief Hails Modi's Assurance on Using India's Vaccine Production Prowess for Global Good

World Health Organization (WHO) chief Tedros Adhanom Ghebreyesus has lauded Prime Minister Narendra Modi's assurance that India will use its vaccine production capacity in helping nations fight Covid-19, saying the pandemic can be defeated only by mobilising resources for common good.

In his address to the 75th session of the UN General Assembly on Saturday, Modi said that "as the largest vaccine producing country of the world, I want to give one more assurance to the global community today. India's vaccine production and delivery capacity will be used to help all humanity in fighting this crisis."

He said that even during these very difficult times of the raging pandemic, the pharmaceutical industry of India has sent essential medicines to more than 150 countries.

"Thank you for your commitment to solidarity, Prime Minister @narendramodi. Only together, by mobilising our forces and

resources jointly for the common good, can we end the #COVID-19 pandemic," WHO Director-General Ghebreyesus said in a tweet. Modi told the 193-member UN General Assembly that in India and the neighbourhood, "we are moving ahead with phase 3 clinical trials in India". Modi further assured that India will also help all the countries in enhancing their cold chain and storage capacities for the delivery of the vaccines.

He, however, questioned the response of the United Nations in combating the pandemic that has so far infected over 32 million people in the world and will soon reach the grim milestone of a million deaths. "Over the last 8 to 9 months, the whole world has been battling the pandemic of the Coronavirus. Where is the United Nations in this joint fight against the pandemic? Where is its effective response?" Modi said.

Melissa Fleming, Under-Secretary-General for Global Communications at the United Nations, said Modi's assurance is welcome news because UN Secretary-General Antonio Guterres had told the General Assembly in his address last week that "vaccinationalism" is not only unfair but self-defeating.

With the COVID-19 pandemic soon reaching the grim milestone of a million deaths, Guterres had chided those countries who are making "side deals" to have a Covid-19 vaccine exclusively for their own populations. "Such 'vaccinationalism' is not only unfair, it is self-defeating. None of us is safe, until all of us are safe. Likewise, economies cannot run with a runaway pandemic," Guterres had said.

— News18 India

Coronavirus LIVE Updates: Proud Moment, Says Serum Institute CEO Adar Poonawalla on PM's Vaccine Assurance to the World

India's Covid-19 caseload neared 60 lakh with 88,600 fresh infections being reported on Sunday, while the number of people having recuperated from the disease crossed 49 lakh pushing the national recovery rate to 82.46 per cent, according to the Union Health Ministry. The total coronavirus cases mounted to 59,92,532, while the death toll climbed to 94,503 with 1,124 people succumbing to the disease in a span of 24 hours, data updated at 8 am showed. Gujarat Chief Minister Vijay Rupani has issued orders that the state government will not organise 'Navrati Mahotsav' this year in view of the Covid-19 pandemic. BJP leader Uma Bharti, meanwhile, became the latest political leader to positive for Covid-19 following mild fever for three days. On Twitter, Bharti asked those who came in contact with her in recent days to get tested as well.

The total recoveries have surged to 49,41,627, and there are 9,56,402 active cases of coronavirus infection in the country which comprises 15.96 per cent of the total caseload, the data stated. The COVID-19 case fatality rate was recorded at 1.58 per cent.

— News18 India



Here's a status update on 10 Covid-19 vaccines that are ahead of the pack

It is arguably the most awaited and widely tracked breakthrough in medicine in modern times. With known global coronavirus cases topping 32 million on September 25, a vaccine for the highly contagious viral infection cannot come sooner. Several Covid-19 vaccine candidates have entered late-stage clinical trials and some are getting ready—the possibility of an effective vaccine in the new year is beginning to look more real.

Around a million people have lost their lives to the outbreak that started in China's Wuhan in late 2019. India is the second-worst hit country, with 92,290 deaths and more than 5.8 million reported infections. For the last several days, India has been reporting the most cases anywhere in the world, with the outbreak showing no signs of abating. India, along with the WHO and the US, has said a vaccine with more than 50 percent efficacy will be acceptable. It means the vaccine has to be at least 50 percent more effective than a placebo to be considered for approval. Officials in the US say that at least 150 COVID-19 infections must be recorded among trial participants, with at least twice as many occurring among the

placebo group.

Here is the lowdown on some of the leading vaccine candidates:

Moderna: mRNA-1273

Moderna had developed a Covid vaccine based on genetic material or mRNA that instructs human cells to make SARS-CoV2 antigen, eliciting an immune response that had a clear head start over rivals.

Status update

The company initiated phase-3, or late-stage, clinical trials on July 27. In Phase-3, the vaccine is being tested on 30,000 participants. As of last week, it had enrolled about 25,000 participants. Moderna's first interim analysis will come after 53 trial subjects become infected. The company plans to seek emergency authorisation for high-risk groups if the vaccine proves effective. The approval is expected in the first half of CY2021 but the possibility of an early approval can't be ruled out.

India availability - Not known.

Pfizer-BioNTech: BNT162b2

Pfizer and German firm BioNTech have developed a Covid vaccine candidate based on genetic material or mRNA that instructs human cells to make SARS-CoV2 antigen, eliciting an immune response. Though they had a late start, the two companies have covered a lot of ground and could create history by being the first vaccine to get US approval.

Status update

They initiated Phase-2/3 or clinical trials on July 27. The vaccine is being tested on 30,000 participants in the US and countries like Argentina Brazil, and Germany. On September 12, Pfizer and BioNTech announced they would seek to expand their US trial to 43,000 participants. Pfizer's first interim analysis will

come after 32 coronavirus trial subjects become infected. By the end of October, it will come to know whether the vaccine works, the company has said. It plans to seek emergency authorisation for high-risk groups if the vaccine proves effective. The approval is expected in the first half of CY2021, but there is a strong possibility of it coming in before the end of 2020.

India availability - Not known

AstraZeneca-University of Oxford: AZD1222

The British-Swedish pharma major AstraZeneca and the University of Oxford are developing a Covid-19 vaccine based on a chimpanzee adenovirus called ChAdOx1 as vector that has been modified to carry coronavirus genes and deliver them into human cells. The vaccine had a headstart, with phase-1 initiated in April. Interim data was published in July.

Status update

Phase-2/3 clinical trials were initiated in May. The vaccine is being tested on more than 12,000 volunteers in the UK and another 5,000 participants in Brazil and South Africa. In India, Serum Institute of India is testing it on 1,700 participants. The company is enrolling 30,000 participants in the US for phase-3. The trial was paused in the first week of September due to an adverse reaction in a volunteer who developed brain inflammation. The trial resumed in all other countries except the US. AstraZeneca said its first interim analysis will come after 75 coronavirus trial subjects become infected. This will give a fair idea of the effectiveness of the vaccine. The data is expected by the Q4CY20. The approval is expected in the first half of 2021.

India availability - The vaccine would be distributed through Serum Institute of India.

Johnson & Johnson: JNJ-78436735

Johnson & Johnson developed Covid-19 experimental vaccine based on adenovirus vector Ad26. The company has used the same viral platform to develop vaccines for Ebola and other viruses such as Zika, RSV and HIV. What sets it apart is that it is a one-dose vaccine compared to two for other vaccine candidates and doesn't need to be frozen for distribution, which will make transportation easy and save costs.

Status update

Johnson & Johnson became the fourth company to initiate a global phase-3 trial. It took just three months for the company to move from phase 1/2 to a late-stage trial. The company plans to enrol up to 60,000 volunteers across three continents and will study the safety and efficacy of a single vaccine dose versus placebo in preventing COVID-19. If proven to be safe and effective, the first batch of the vaccine should be available for emergency use in early 2021.

India availability - The vaccine would be distributed through J&J partner Biological E.

Novavax: NVX-CoV2373

Novavax has spent three decades and burnt \$1.5 billion trying to develop vaccines based on its recombinant nanoparticle technology and Matrix adjuvant platform without much success. It's hoping Covid-19 will turn the tide. Novavax vaccine is a protein sub-unit vaccine that uses part of the virus and combines with adjuvant, or booster, to deliver it as a vaccine. The vaccine doesn't need to be frozen for distribution, making it much easier to handle.

Status update

Novavax initiated phase-3 trial on September 24 in the UK. The trial is being conducted in partnership with the UK government's Vaccines Taskforce, and is expected to enroll up to 10,000 individuals between

18-84 years of age over the next four to six weeks. The company expects to roll out the vaccine by mid-2021. In September, Novavax reached an agreement with the Serum Institute of India to produce as many as 2 billion doses a year. The vaccine has to be given in two doses.

India availability - Vaccine would be manufactured and distributed by its partner Serum Institute of India

Sputnik vaccine

Sputnik V, the Covid-19 vaccine developed by Moscow's Gamaleya Institute, the Russian Defence Ministry and the sovereign Russian Direct Investment Fund, became the first vaccine to be cleared for public use even before being tested for safety and efficacy. The vaccine is based on a modified human adenovirus as vector, which carries the protein of the SARS-CoV-2 virus. On September 16, RDIF reached an agreement with Dr Reddy's to conduct clinical trials and distribute 100 million doses of vaccine in India.

Status update

The results of Sputnik V of Phase 1/2 clinical trials on 76 people were published in The Lancet early September, showing that the vaccine candidate triggered a strong immune response. Russia is enrolling 40,000 volunteers as part of phase-3, starting September. The trial will take six months to complete. Media reports suggest that the vaccine is available for public in Russia but the vaccine may not be available in other countries at least until the first half of CY21. The vaccine has to be given in two doses.

India availability: Vaccine would be distributed through Dr Reddy's.

Bharat Biotech: Covaxin

Bharat Biotech is developing a Covid vaccine in

collaboration with the Indian Council of Medical Research (ICMR). ICMR's National Institute of Virology (NIV) had transferred the SARS-CoV-2 virus strain. Bharat Biotech has developed an inactivated vaccine based on the strain. The vaccine has been found to have elicited immune response in monkeys.

Status update

Bharat Biotech initiated Phase-1 and 2 trials in July. The company plans to launch Covaxin Phase -3 trials in October, where it will test the vaccine on about 25,000-30,000 volunteers in India and other countries. The vaccine is unlikely to be launched until the first half of 2021. Bharat Biotech is making the vaccine at risk. Currently, it has capacity to manufacture 100-200 million doses at two of its Biosafety Level (BSL) -3 facilities in Hyderabad. It is trying to rope in partners who can increase the capacity to 1 billion doses per annum. The vaccine has to be given in two doses.

India availability - The vaccine will be distributed by Bharat Biotech

Zydus Cadila: ZyCoV-D

Zydus Cadila has taken a novel approach to its potential Covid-19 vaccine. Called plasmid DNA, the vaccine consists of genetic material of SARS-CoV-2 proteins that instructs human cells to make SARS-CoV2 antigen, eliciting an immune response. The company says that this approach is easily replicable and scalable, requiring just Biosafety Level (BSL)-1.

Status update

Zydus Cadila initiated Phase-1 and 2 trials in July. The company plans to test the ZyCoV-D vaccine on about 15,000-20,000 people in Phase-3. The launch of the vaccine is expected in the first half of 2021.

India availability - Vaccine would be distributed by Zydus Cadila

Sanofi-GSK

Sanofi-GSK Covid vaccine lags behind but given that the vaccine comes from Sanofi, which has a huge manufacturing and distribution presence in India, its progress will be closely watched. The vaccine is based on a protein subunit, with adjuvant (booster) provided by GSK.

Status update

The companies said the pre-clinical studies showed promise regarding safety and immunogenicity of the vaccine. On September 3, Sanofi and GSK announced the initiation of Phase 1/2 clinical trials. Over 400 participants are enrolled for Phase 1/2 study. Pending positive Phase 1/2 data, companies aim to move into Phase 3 by the end of 2020. Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant with the target of producing up to one billion doses in 2021. The vaccine is likely to be available in the second half of CY21.

India availability - The vaccine could be available to India through Covax.

Cansino

The Chinese vaccine candidate based on human adenovirus Ad5 vector developed by CanSino Biologics and Beijing Institute of Biotechnology and Academy of Military Medical Science has become a major tool for China's vaccine diplomacy. The vaccine has been approved by the Chinese military on June 25 for a year as a "specially needed drug".

Status update

Cansino vaccine entered phase-3 in August with plans to enrol 40,000 participants. China has got approvals in Russia, Pakistan, Saudi Arabia, for conducting phase-3 trials. Possible launch in second half of CY21.

India availability - Not known

-Moneycontrol.com

Covid-19: India inching closer to 1% death rate

India's positivity rate of coronavirus disease (Covid-19) may have been hovering around 8% for a while now, but the death rate has been declining gradually, highlighting the fact that India is losing fewer people to the viral disease as compared to most of the developed countries in the world. India's case fatality rate (CFR), the proportion of people who have died among the confirmed cases, at 1.5% is nearly half of the global average of 3.2%. The Centre is aiming at bringing down the CFR to 1% or below.

Government mortality analysis data shows that men are far more likely to die from Covid-19 in India than women, with the former accounting for 69% of all fatalities, which is in line with the global scenario and based on the evidence currently available.

The analysis of mortality data by the Union health ministry also shows that a majority of deaths were among those above 50 years of age. It showed that 1% of those who succumbed to the viral infection were below 17 years; another 1% between 18 and 25 years; 11% deaths among 26- and 44-year-olds; and 36% among people in the 45 to 60 years age group.

People with comorbidities and elderly are at high risk, as almost 70% of those who die have one or more comorbidities such as hypertension, diabetes, cardiac, renal or liver disease. The data collated by government's integrated disease surveillance programme based on the information received from various hospitals across the country shows that

about 77% of those hospitalised had some form of underlying medical condition. Many of those who succumbed to disease had been suffering from more than one condition. Hypertension and diabetes are the most common comorbidities found in these patients, with 5.63% and 5.10% hospitalised patients suffering from it respectively. Liver disease is a close third with at least 1.82% of the patients being diagnosed with it.

The other common health conditions included heart disease, asthma, chronic renal disease, chronic obstructive pulmonary disease (COPD), low immunity, malignancy, bronchitis and chronic neuromuscular disease.

- Hindustan Times



Hyve India Pvt Ltd has come up with a weekly e news alert program - 'Market News & Views'

This program will cover Industry Updates, Launch of New Technologies, Partnership Opportunities, Industry Views & CSR activities. The purpose of this program is to keep customers up to date with developments in the Industry.

INDUSTRY UPDATES



Lego to Replace Plastic Bags With Paper in its Boxed Sets

Lego, as well as other big brands, have been looking for ways to cut plastic use in order to please customers increasingly worried about how their purchases impact the environment.

Lego has announced that it will stop using plastic bags inside its boxed sets and replace them with paper ones. The Danish toymaker has announced that it will start making the switch next year and expects plastic bags to be completely phased out in the next five years. The bags are used to hold loose bricks in boxed sets.

Monopoly maker Hasbro, for example, has also announced plans to eliminate plastics in its packaging.

Among the environmental issues posed by plastic is that it doesn't disintegrate. Instead, it breaks down into tiny pieces that can be eaten by birds or other wildlife, endangering their health.

Lego's colourful bricks are also made of plastic, but the company has had trouble finding another material that's as durable. About 2 percent of its pieces, such as Lego trees and bushes, are made of sugar cane, Lego said kids wrote the company asking it to drop the plastic bags.

"We have been exploring alternatives for some time and the passion and ideas from children inspired us to begin to make the change," said Lego CEO Niels B Christiansen, in a prepared statement.

The paper bags, which are recyclable, are easier for kids to open, the company said.

– Paper Mart

Paswara Papers Begins Production at its New 36000 MTPA Kraft Board Unit

Paswara Papers Limited has commenced the production at its new Kraft Board Unit – PM3. The installed capacity of the new plant is 36000 MTPA. The company will produce 12BF to 22BF Kraft board in the range of 270 GSM to 600 GSM. The new unit will also produce plybond board in the range of 270 GSM to 450 GSM. The new plant will mainly cater to speciality paper market.

As informed by Paswara Papers Limited – finished deckle size of the machine is 1900 mm and is designed to run at a speed of 100 MPM. It is a mould machine. The technology and equipment have been sourced from the domestic suppliers. The raw material used is brown waste paper sourced from both domestic and overseas suppliers. The estimated cost of the project is INR 80 crore. The commercial production was

commenced on August 31, 2020.

Mr. Deept Agarwal from Paswara Papers further states, "This board has its niche market. It is mainly used for making of cones and pipes. We are also developing kappa board in which this Kraft board will be used primarily."

– Paper Mart



Valmet to supply Metsä Board's Kemi mill with Industrial Internet solutions to enhance end-product quality and the mill's productivity

Valmet and Metsä Board have signed an agreement on data-driven optimization of paperboard quality of the board machine at Metsä Board's Kemi mill. The machine produces premium quality white top kraftliner. Valmet will supply the mill with Valmet Industrial Internet VII Data Discovery and VII for Paper Quality solutions.

The agreement is the first step in a jointly built digital roadmap between Metsä Board and Valmet. The target of this first step is to ensure top-quality end-product to enable smooth runnability in the paperboard converting process. A mill-wide action plan will be created by combining historical mill process data, converting data from Metsä Board's customer and Valmet's expertise to discover the improvement potential of the board machine BM1 production process. This is enabled by Valmet's VII Data Discovery solution.

"Metsä Board's products are known for high quality consistency and converting runnability, and we are committed to continuous improvement. With virtual sensors for quality management using artificial intelligence we can reach even better performance. We chose Valmet as our partner based on technical expertise and long-term trust between our companies," says Tomi Vähä-Ruohola, Technical Development Manager, Metsä Board.

"This project is a good example of how we can use VII Data Discovery findings to build a mill-wide action plan and create the right artificial intelligence-based VII solutions for the customer's needs. With this first step in our common digital roadmap, we are together moving towards data-based optimization of the entire value chain from pulping to converting," says Arttu-Matti Matinlauri, Director, Analytics and Applications, Automation business line, Valmet.

About Valmet's delivery

The VII for Paper Quality solution, including Valmet's artificial intelligence-based applications and the Valmet IQ Quality Management System are used to predict and autonomously optimize paperboard surface quality in real time. A key part of the VII for Paper Quality solution is the world's first predictive application for online optimization of paperboard surface quality. It helps maintain high end-product quality and optimize the usage of raw material. Another important application in this solution is the Dynamic Centerline Advisor, which builds optimal production recipes for each operating mode, ensuring maximized overall equipment effectiveness.

About Metsä Board

Metsä Board is a leading European producer of premium fresh fibre paperboards and forerunner in sustainability. Metsä Board produces premium lightweight folding boxboards, food service boards and white kraftliners for consumer goods packaging as well as retail-ready and food service

applications. In 2019, the company's sales totalled EUR 1.9 billion, and it has approximately 2,400 employees. Metsä Board, part of Metsä Group, is listed on the Nasdaq Helsinki.

- Papnews





PKV to invest heavily in cartonboard production

Papier- und Kartonfabrik Varel (PKV) is continuing to consistently implement its strategic program, which comprises a total of 280 million Euro, with future-oriented investments in its cartonboard production.

In a very wide range of cartonboard products, the high grammages have always been a specialty of Varel.

These days, engineers and fitters are putting the finishing touches to major investments in equipment for PKV board production: board machine 2 will soon be able to use a completely new online sheeter, and the sheeter of board machine 3 has been extensively modernized. Both machines from the renowned Spanish manufacturer Pasaban will thus ensure even higher quality in board production in future. Among other things, this will include further improved state-of-the-art precision cutting, higher availability and thus a larger cutting capacity, so that the company is well prepared for further investments in board machines.

"High-quality cardboard made of waste paper

is sustainable, flexible and resilient - this product has a future," says PKV shareholder Kristian Evers. "In Varel, we have always made sure that we are as broadly based as possible for our customers. These investments will help us to move forward - together with our outstanding know-how, especially in the area of high grammages."

Cardboard is produced in Varel in basis weights between 350 and 1400 g/m², as gray or brown board, GD or GT and laminated quality. All products are FSC-certified and recyclable in accordance with the EN 13430 standard. Customers use the versatile and high-quality products in the food industry, for industrial solutions, point-of-sale packaging or, for example, for heavy-duty shipping envelopes made of brown cardboard. In cooperation with the PKV sister company Jade-Pack, PKV cardboard and paper are also used to create special solutions for the highest technical requirements in the packaging of food and industrial goods. Further investments in cartonboard production are in preparation, for example a modernization of the stock preparation. The Varel paper and board mill will further develop its plant in the coming years to a production capacity of one million tons of corrugated board paper and board. As has been the case since 1950, the raw material for this will be recycled waste paper. At the same time, PKV continues to improve its energy efficiency through numerous investments. All these projects are part of a seven-year strategic program with a total volume of around 280 million euros, which PKV is currently implementing to strengthen and modernize the site.

– PULPAPERnews.com

A.Celli to supply an E-WIND® T80S rewinder to Aktül Kağıt

The Turkish Tissue producer chooses A.Celli Paper for its new investment. Aktül Kağıt is a company that produces one of the softest toilet paper and most absorbent paper towel in Turkey with eco-friendly production practices. Aktül Kağıt started to produce tissue paper from 100% virgin wood pulp in September 2011. Currently it produces private label products for leading local and abroad chains markets and also supply quality jumbo rolls for many converting facilities, located both in Turkey and abroad. So it is with extreme satisfaction that A.Celli Paper S.p.A. announces the start of a precious collaboration with Aktül Kağıt through the agreement for the supply of a latest-generation E-WIND® T80S rewinder for the production of tissue.

A.Celli Paper E-WIND® T80S is a modular and fully automated rewinder, running at 1000 mpm, with built-in electrical cabinets and capable of managing products that involve a specific volume, diameter and cutting format while also guaranteeing extra capacity during production peaks. It is customisable, plug-and-play, perfectly adaptable and compatible with any standard rewinding system or complete line in the tissue sector.

Yet another confirmation for A.Celli Paper technology which is even more present and able to meet the needs of different customers, responding promptly and flexibly to the variegated production variables.

– Papnews

INDUSTRY SPEAK



Piyush Patel
MD
Amtech Electronics (India) Ltd.

We at Amtech are committed to support our customers in Pulp & Paper Industry in the current pandemic situation. During the lockdown, our sales and service department assured that our customers do not suffer in case of any problem. We provided remote guidance / assistance in case of any technical issues and resolved successfully. The new projects are worst affected by the deliveries of the equipment. But Amtech has kept the momentum going on. We are working hard to meet the deliveries and ensure that our customers are least affected by the current situation. We believe in serving India and the entire world through products designed & developed by Indians and Made in India - Made for the World. We offer our customer the NextGen Technology which reduces overall energy consumption, improves paper quality & productivity, provides flexibility in operation and better monitoring of plant. It is our pleasure and

pride to have customers like you who recognize the Brand India and are truly Vocal for Local. For over 30 years we are providing Total Solutions in motor control automation, power quality & energy conservation and industrial electronics to our most discerning clients in the paper industries. We crafts energy saving, speed regulation and intelligent control strategies in to their daily workings to improve the bottom line.



MEDIA SPEAK

Paperboard Market to Reach USD665.85 Billion by 2027

The rapid growth of e-commerce and the growing demand for packaging food and beverages are the drivers for the Paperboard market.

The global paperboard market is forecast to reach USD665.85 billion by 2027, according to a new report by Reports and Data. Paperboard is a thick paper material consisting of a compressed layer of paper pulp. It is extensively used for packaging as its easy-to-open, and reseal packaging designs provide benefits to them and end-users. Besides, it is environmentally friendly and can be recycled. Retailers and product manufacturers also enjoy great benefits from paperboard packaging. It can be placed, stored, and displayed effectively on retail shelves.

The most important properties of paperboard, the driving force of the market, are its recyclability, its reusability and its durability. Also, the growing awareness of ecological conservation makes consumers inclined to use paperboard. Besides, high-resolution graphics and two-sided printing of paperboard can enhance the brand promotion of products. Therefore, various product manufacturers choose it as packaging material.

As the boxes are not able to withstand the mechanical stress of heavy materials, they are not used in the packaging of heavy materials. Therefore, some heavy goods manufacturers do not prefer paperboard for packaging. Also, strict government regulations on deforestation would slow its growth, since it is

produced mainly from wood. Growing environmental awareness among emerging economies in the Asia-Pacific, like India and China, would lead to its usage in packaged foods.

The COVID-19 impact:

The COVID-19 pandemic is expected to have a downward impact on the global Paperboard market in 2020, the reason being the halt in the industrial and commercial production applications of durable goods, which was responsible for the significant demand in 2019. After the pandemic, however, trends discussed in the study of the Global Paperboard Market do hold ground.

Also, fear of contamination from food and beverages from restaurants with most of them closing operations has resulted in a downgraded outlook for the industry, which will have short-term impacts on global sales that could have lasting effects. While the industry expects things to return to near normal state well before the end of 2020, negative demand shock caused by the crisis is likely to last.

Further key findings from the report suggest:

- o Asia-Pacific has a significant share of the global paperboard packaging market. Emerging foods and beverages, electronics, consumer products, and the pharmaceutical industry as a result of economic development will fuel the demand soon. Another factor affecting the market is the increase in income level and technological development in the pharmaceutical industry. The region will experience a growth rate of 5.4% during the forecast period.

- o North America will experience stagnant growth in the global paperboard

packaging sector due to the maturity of the market in this region. In 2019, the segment represented around 22.0% of the entire sales.

- o The European region will experience moderate and steady growth due to government-imposed paper recycling regulations. The segment generated USD95.76 billion in the world market in 2019.

- o The Containerboard segment held the largest share because of its extensive usage in E-commerce and electronic product packaging.

- o Fresh sources are estimated to lead the material type segment with a significant CAGR because of the risks involved in the usage of recycled waste paper.

- o The food and beverage segment is estimated to capture a massive share of the market because of the flourishing of the take-out food consumption and changing lifestyle patterns of individuals.

- o Key participants include Nippon Paper Industries Co., Ltd., Mondi plc, ITC Limited, International Paper Company, Metsa Group, Smurfit Kappa Group plc, South African Pulp & Paper Industries Limited (Sappi Limited), Stora Enso Oyj, Rock-Tenn Company, and Oji Holding Corporation, among others.

– Paper Asia



School Effect: Demand for W & P Paper may slightly revive in October-November

After being closed for more than six months, Government of India has decided to reopen the schools for students of 9th to 12th classes on a voluntary basis across the nation from September 21st onwards. Standard Operating Procedures (SoPs) for partial reopening of schools outlines various generic precautionary measures to be adopted in addition to specific measures to be taken when schools are permitting students (for 9th to 12th class) to prevent spread of COVID-19. This step may bring a 'sigh of relief' for Paper Industry as demand for writing and printing (W & P) paper may revive in October or November month. "Yes, we are hoping that demand for W & P paper will get a little boost in coming months as the government's decision to reopen the schools will slowly increase the consumption of printed books, and as well for the printing of next academic session's books in March month, publishers will start placing orders for paper in October-November," said by a well placed sources in Khanna Paper Mills, a renowned manufacturer of different grade of writing and printing and packaging paper in Northern India.

According to sources, the demand for W& P paper has been plummeted by 60 to 70 percent since the lockdown announced in the country due to Corona pandemic.

Around 40% of the students had their parents' consent for coming to school from Monday: "Along with sanitising the students and checking their temperatures, we will also

check their blood oxygen levels using oximeters to screen for asymptomaticity. An isolation room will also be allotted within the school in case any student or faculty member feels unwell," a principal of a reputed school added.

To avoid the demand crush, paper mills has also diverted their production on packaging paper also, "we are manufacturing 2000 MT kraft paper every month, supplying it to local corrugators and traders in North. Our GSM range for kraft paper is 60 to 70 GSM under 20 to 22 BF," sources said.

"We are seeing a little revival in copier paper demand as children are having printer facility at their homes," Sources informed.

– *The Pulp and Paper Times*



US packaging papers & specialty packaging shipments increased in August

The American Forest & Paper Association (AF&PA) has released its August 2020 Packaging Papers & Specialty Packaging Monthly report. According to the report, total packaging papers and specialty packaging shipments in August increased one percent compared to August 2019. They were up three percent when compared to the same eight months of 2019.

The operating rate was 85.2 percent, down 2.7 points from August 2019 and down 1.0 points year-to-date.

Mill inventories at the end of August increased 4,000 short tons from the previous month and were up 12,000 short tons compared to August 2019.

The American Forest & Paper Association (AF&PA) serves to advance a sustainable U.S. pulp, paper, packaging, tissue and wood products manufacturing industry through fact-based public policy and marketplace advocacy.

– *PULPAPERnews.com*

NEW TECHNOLOGIES

Proklean Technologies Pvt. Ltd.

Proklean Technologies is introducing:

ProCharta range of Bleaching Enhancers

- ProCharta ProBleach – Bleaching Booster for Recycle Paper
- ProCharta ProRB – Bleaching Enhancer for Reductive Bleaching
- ProCharta ProWhite – Delignification & Bleaching Enhance

Proklean Technologies Pvt. Ltd. has developed a unique, first-in-the-world proprietary technology under the ProCharta umbrella for paper industry. ProCharta formulations are manufactured on the platform of “probiotics technology” and are high performing, non-toxic and readily biodegradable. They replace / significantly reduce some of the chemicals used in industries like Pulp & Paper, Textile, Leather, etc.,

Other range for Pulp and Paper Industry:

- ProCharta ProYield – Yield Enhancer for Pulp Mills
- ProCharta ProEnviro – Odour Controller for Pulp Mills
- ProCharta ProSolve – Odour Controller for Kraft Mills

Chemistry Behind Our Technology:

Bleach Enhancers:

Bio-chemicals produced by probiotics have Caustic buffering, high antioxidant ability and are known to chelate Magnesium / Copper / Iron ions due to the physiological chelators that exist in the intracellular cell-free extract of probiotics. Our formulations developed for bleaching applications inhibit these metal ions from decomposing

bleaching chemicals and thereby greatly enhance the bleaching results. The surfactant present in our range of Bleach Enhancers will ensure right brightness is maintained at a lower dosage of Bleaching Chemicals.

Yield & Kappa Improvement:

Our formulations developed for application at Cooking stage are essentially biodegradable bio-surfactants which are free of anthraquinone. The surfactant character enables better penetration of cooking liquor which helps in dissolving lignin and other derivatives. This results in lowering the kappa number without degradation of fiber, thereby improving yield marginally.

Odour Control:

Typically, odour is caused by volatile compounds of Sulphur and nitrogen. There are two mechanisms of odour reduction by ProCharta products:

1. The biochemicals present in the formulation have the ability to react with the volatile organic compounds and convert them to non-odour causing soluble compounds and hence reduce odour
2. Two microbe species present in product, which are resistant to high temperatures, are also capable of using Sulphur and Nitrogen as their energy source and hence consume the same, thereby reducing the generation of odour causing volatile compounds.

These products now in regular commercial use in many large paper mills in India. All products are REACH compliant and FDA certified.



Amtech Electronics (India) Ltd.

The internet and globalization has opened the door of information and competition respectively. Every industry is going through the pressure of cost competitiveness without compromising the quality. Pulp & Paper Industry is no more exception.

Amtech is a leading from front to help our customers as far as the electrical needs are concerned. From 2-pole structure to plant monitoring, we do everything! Our products and solutions are indigenously developed in our in-house R&D. Our products are Made in India – Made for the World.

The key areas of improvement which brings the competitiveness as well as improves the quality are the energy consumption and productivity. With NextGen solution, Amtech helps customer to save energy and improve productivity. Amtech's NextGen Technology is embedded with unique algorithm, a combination of efficient hardware and intelligent software, which ultimately improves the efficiency and productivity. The NextGen Automation Software is the result of our three decades of experience in motor control and automation solutions. The focus is on efficient and reliable integration of various hardware peripherals, optimize processes with fast response and increase communication capabilities. The NextGen Automation Architecture reduces field cabling and increases reliability. This architecture gives smart controlling and monitoring of plant with proactive actions to give highest uptime. The NextGen Smart Drives with Enhanced efficient control algorithm of Architecture class improves dynamic response of speed and torque

control. Built with next generation efficient components improves efficiency and reliability. Emphasize is on easy commissioning, easy connectivity and easy fault diagnosis. The NextGen Technology correlates all paper parameters with its integrated solution. This takes down all data viz. GSM, Steam, Power, monitoring of all the motors in plant whether they are running on VFD, Soft Starter, DOL, start/delta starter for running status, current, fault etc and gives energy management in real sense. Intra-logistic solutions open the opportunity to handle finished paper for dispatch. Amtech provides NextGen Turnkey Electrical & Automation solutions for Green field projects of any size of plant and type of paper. Amtech is also offering Emerging Industry 4.0 Solutions for Smart Factory. Our innovative solutions are NextGen Turnkey Pulp and Paper plant Automation, Sectional paper machine Automation with VFD, Headbox Automation, Steam and Condensate system Automation, Pulp mill process control with VFD, Rewinder, Coater and Super calendar, Boiler Automation, Energy Management system, Retrofitting of DC motor and drive system to AC motor and drive system in Sectional paper machine and Line shaft to Sectional paper machine, Integration of third party drives with our control system in Sectional paper machine, Efficient Control system for complex operations like Multi wire control, Silent drive control, load sharing, tension control, Master/follower operation, Close loop control etc.



BUSINESS FESTIVAL OF PAPER INDUSTRY



a Hyve event

6 - 9 December 2021

Pragati Maidan, New Delhi India

Paperex is the largest paper industry event in the world and it takes place in New Delhi, India.

It is a "A Unified Business Platform for Paper Industry" for new business opportunities, joint ventures, investments and technology transfer in paper and allied industries.

Paperex is always very well attended by large gathering of Paper Manufacturers to explore the New Technology., Machinery & Equipment and Raw Material for Paper & Board Manufacturing.

And the mass audience of Paper Traders, Printers, Publisher, Converter and Paper Packaging Companies to explore the variety of papers at the show



08-10 April 2021

Chennai Trade Centre, India

A sneak Preview:

- Meet 250+ exhibitors who will display latest products & services from 18 countries
- Learn new trends by attending technical conference by IARPMA
- Network with industry leaders at "Global Paper Technology Supplier" pavilion
- Delegation program to host international buyers
- 5000+ trade visitors from 20+ countries including 142 paper mills across India
- Visit "Paper Manufacturer" networking pavilion
- Engage with the leaders at "Exclusive Paper Mills CEO/MD Conclave"

Business Connect Program

- **Market News & Views, a weekly e news alert program** covering Industry Updates , Launch of New Technologies , Partnership Opportunities , Industry Views, CSR activities
- **International Business Networking Program (IBNP) a monthly webinar** covering key industry across Indian as well as some neighboring countries including China, Taiwan, Bangladesh, etc
- **Open Seminars during the event**, a unique opportunity to have face to face interaction with industry leader and knowledge transfer



Contact Us



Hyve India Private Limited

(CIN. U92490DL2004PTC124343)

Innov8 , 2nd Floor, 44, Regal Building

(Above Madame Tussauds Wax Museum)

Outer Circle, Connaught Place, New Delhi-110001, INDIA

Email: ed.india@hyve.group

Website: india.hyve.group, www.hyve.group

SOME LEADING COMPANIES AT THE EVENT



Proklean Technologies Pvt. Ltd.



Proklean Technologies Pvt Ltd (Proklean) is a company which develops and markets high performing, non-toxic and fully bio-degradable products which replace some of the chemicals being used in certain industries. Currently the company serves Textile Processing, Leather Processing, Pulp & Paper and Hospitality industries. The first in the world technology uses a combination of naturally occurring Probiotic microbes and certain natural/bio-degradable ingredients to develop the products. A proprietary

fermentation and formulation process is used to produce the final products. The products have been tested in third party laboratories to show that they are non-toxic as well as 100% bio-degradable and have third party certifications for industry standards.

The unique features and benefits of the products are:

- High performance – In most situations, Proklean products deliver better results than the chemicals being used now
- Non-toxic and fully bio-degradable – significant reduction in pollution and safe for the users and environment
- Works at wide range of pH and temperature – flexible operating parameters; no need to adjust pH and temperature
- Innovative, low cost production technology ensures that Proklean products are competitively priced compared to the chemicals

The Company has marquee customers such as Raymonds, Mafatlal, Welspun, Vardhaman, ITC, TNPL in India and its products are also sold in Bangladesh, Ethiopia, South Africa, Thailand, China, Germany, Hungary, Philippines, Turkey and U.S.A. Stahl, a world leader in Leather Chemicals has taken up exclusive distribution of the leather processing products. Please visit www.proklean.in for more information on the company and its products.

Amtech Electronics (India) Ltd.



Amtech an Indian Multinational, for over 30 years has been providing Total Solutions in motor

control automation, power quality & energy conservation and industrial electronics to its most discerning clients in the paper industries. It is located in Gandhinagar, Gujarat. For more information visit www.amtechelectronics.com or write to info@amtechelectronics.com

We have successfully executed projects like, 30 TPD to 500 TPD, 14 GSM to 500 GSM, Kraft, Duplex, Tissue, Newsprint, Writing & Speciality Paper, Multi Layer Wire, Bi-Nip Press, Silent Dryer, Tension Control & Close Loop Control, Headbox Automation, 80 MPM to 1200 MPM, Steam & Condensate Automation, Trim Drum Slitter Rewinder Automation with Tension control, Pulp mill process control with VFD, Boiler Automation, Approach Flow Automation

Karan Carpet Industries:



Manufacturer of Synthetic Felt and Dryer Screen

The Key Features:-

1. Better Quality.
2. Better Price
3. Faster Delivery.



...and many more



...and many more

Thank You

COMBATING
COVID-19

Basic
Protective
Measures



USE FACE MASK



CLEAN AND DISINFECT



WASH YOUR HANDS
FREQUENTLY



KEEP DISTANCE
FROM OTHERS



AVOID TOUCHING
EYES, NOSE OR MOUTH



STAY AT HOME
WHEN YOU ARE SICK